Document Detail


What Are New Avenues for Renal Protection, in Addition to RAAS Inhibition?
MedLine Citation:
PMID:  22298106     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Diabetic nephropathy is the leading cause of end-stage renal disease, with both the incidence and prevalence continuing to increase worldwide. Current treatments include optimization of glycemic and blood pressure control by targeting the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II receptor blockers. More innovative strategies are needed to prevent and treat this disease. New agents and approaches have recently been described that have the potential to delay the progression of diabetic kidney disease and minimize the growing burden of end-stage renal disease. Possible targets include the formation of advanced glycation end products (AGEs) and the AGE receptor, increased oxidative stress and inflammation, protein kinase C, endothelin receptors, growth factors and cytokines, the vitamin D receptor, Rho-associated kinases, and the renal sympathetic system. This article reviews these recent developments as potential therapeutic interventions that may prevent this disease, with targets generally beyond the RAAS.
Authors:
Shinji Hagiwara; Phillip Kantharidis; Mark E Cooper
Related Documents :
16780226 - Intravenous cyclophosphamide pulse therapy is effective for refractory graves' ophthalm...
17074526 - Ocular neovascularization: implication of endogenous angiogenic inhibitors and potentia...
17362266 - Polymorphisms of interleukin (il)-4 receptor alpha and signal transducer and activator ...
19839886 - Graves' disease associated with primary systemic sclerosis.
2643636 - Skin diseases aggravated by pregnancy.
19319966 - Adipose tissue: a motor for the inflammation associated with obesity.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-2
Journal Detail:
Title:  Current hypertension reports     Volume:  -     ISSN:  1534-3111     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
JDRF Danielle Albert Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, 3004, Australia, Shinji.Hagiwara@bakerIDI.edu.au.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carbon monoxide-controlled synthesis of surface-clean Pt nanocubes with high electrocatalytic activi...
Next Document:  Correlates of Attachment Perceptions in Parents of Children with Autism Spectrum Disorders.